keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis arthritis

keyword
https://www.readbyqxmd.com/read/28527093/income-disparities-in-healthcare-use-remain-after-controlling-for-healthcare-need-evidence-from-swedish-register-data-on-psoriasis-and-psoriatic-arthritis
#1
Sofia Löfvendahl, Anna Jöud, Ingemar F Petersson, Elke Theander, Åke Svensson, Katarina Steen Carlsson
We used a southern Swedish cohort of psoriasis (PSO) and psoriatic arthritis (PsA) patients and population-based referents (N = 57,800) to investigate the influence of socioeconomic and demographic factors on the probability of healthcare use and on healthcare costs when controlling for need as measured by PSO/PsA and common additional morbidities such as diabetes, depression and myocardial infarction. People with PSO/PsA were identified by ICD-10 codes in the Skåne Healthcare Register 1998-2007. Resource use and costs for years 2008-2011 were retrieved from the Skåne Healthcare Register and the Swedish Prescribed Drug Register, and socioeconomic data were retrieved from Statistics Sweden...
May 19, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28521047/musculoskeletal-ultrasonography-for-psoriatic-arthritis-and-psoriasis-patients-a-systematic-literature-review
#2
Alen Zabotti, Francesca Bandinelli, Alberto Batticciotto, Carlo Alberto Scirè, Annamaria Iagnocco, Garifallia Sakellariou
Objective.: To systematically review the role of musculoskeletal US in patients suffering from PsA or psoriasis (Pso) in terms of prevalence, diagnosis, prognosis, monitoring and treatment. Methods.: A systematic literature review was conducted through medical databases (MEDLINE via PubMed, Embase) and the grey literature up to September 2015 to inform a new study of the Musculoskeletal Ultrasound Study Group of the Italian Society for Rheumatology. All articles reporting data on musculoskeletal US in PsA or Pso were included and extracted according to the underlying clinical question...
May 18, 2017: Rheumatology
https://www.readbyqxmd.com/read/28514463/pediatric-psoriasis-comorbidity-screening-guidelines
#3
Emily Osier, Audrey S Wang, Megha M Tollefson, Kelly M Cordoro, Stephen R Daniels, Andrew Eichenfield, Joel M Gelfand, Alice B Gottlieb, Alexa B Kimball, Mark Lebwohl, Nehal N Mehta, Amy S Paller, Jeffrey B Schwimmer, Dennis M Styne, Abby S Van Voorhees, Wynnis L Tom, Lawrence F Eichenfield
Importance: Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. Objective: To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence...
May 17, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28513835/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2017
#4
C H Smith, Z K Jabbar-Lopez, Z Z Yiu, T Bale, A D Burden, L C Coates, M Cruickshank, T Hadoke, E MacMahon, R Murphy, C Nelson-Piercy, C M Owen, R Parslew, E Peleva, E Pottinger, E J Samarasekera, J Stoddart, C Strudwicke, V Venning, R B Warren, L S Exton, M F Mohd Mustapa
The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. Biologic therapies have now been in use for over 10 years, and with accrued patient-years exposure and clinical experience, many areas that were covered in previous versions of the guideline are now part of the Summary of Product Characteristics (SPC) and/or routine care so that specific recommendations are redundant (see Toolkit A: Summary of licensed indications and posology for biologic therapy, in Supporting information 2)...
May 17, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28512993/hla-cw6-positive-patients-with-psoriasis-show-improved-response-to-methotrexate-treatment
#5
J West, S Ogston, J Berg, C Palmer, C Fleming, V Kumar, J Foerster
It is well documented that patients with human leucocyte antigen (HLA)-Cw6+ (type 1) psoriasis have increased severity and reduced age of onset of psoriasis. However, not much is known about any differential response of this genetic subgroup to various treatments. We set out to determine if there was any genetic association of the HLA-Cw6 allele with the first-line systemic treatment commonly used in psoriasis, methotrexate. A cohort of patients from Tayside in Scotland was recruited through a novel generic consenting process (GoShare); they were extensively phenotyped and analysed for an association of their HLA-Cw6 genotype status with treatment outcomes...
May 17, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28507491/association-between-mean-platelet-volume-and-disease-severity-in-patients-with-psoriasis-and-psoriatic-arthritis
#6
Sevilay Kılıç, Hatice Reşorlu, Selda Işik, Sibel Oymak, Ayla Akbal, Meliha Merve Hız, Zerrin Öğretmen
INTRODUCTION: Mean platelet volume (MPV) is an important marker that shows the activation and function of the platelets, which is effective in the inflammatory diseases. AIM: To show the relationship between MPV and the development of psoriatic arthritis (PA) in patients with psoriasis vulgaris (PV) and the correlation between MPV and psoriasis severity score (PASI). MATERIAL AND METHODS: Our study included 116 patients with psoriatic arthritis (68 female, 48 male) and 41 patients in the psoriasis group (19 female, 22 male) and 90 subjects in the control group (55 female, 35 male)...
April 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28507445/evaluation-of-fatigue-and-its-correlation-with-quality-of-life-index-anxiety-symptoms-depression-and-activity-of-disease-in-patients-with-psoriatic-arthritis
#7
Claudio Carneiro, Mario Chaves, Gustavo Verardino, Ana Paula Frade, Pedro Guimaraes Coscarelli, Washington Alves Bianchi, Marcia Ramos-E-Silva, Sueli Carneiro
BACKGROUND: Psoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue. OBJECTIVES: This study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity. PATIENTS AND METHODS: This cross-sectional study was performed on outpatients with psoriatic arthritis...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28506203/optimization-of-microemulsion-based-transdermal-gel-of-triamcinolone
#8
Bhagyashree Chaudhari, Swati Jagdale
BACKGROUND: Triamcinolone is a long acting corticosteroid used in the treatment of arthritis, eczema, psoriasis and similar conditions which causes inflammation. Triamcinolone has half-life of 88 minutes. Prolonged oral use is associated with gastrointestinal adverse effects as peptic ulcer, abdominal distention and ulcerative esophagitis. Microemulgel offers advantage of better stability, better loading capacity and controlled release especially for drug with short half life. OBJECTIVE: Objective of the present study was to optimize microemulgel based transdermal delivery of triamcinolone...
April 25, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28506134/efficacy-and-safety-of-etanercept-in-psoriasis-and-psoriatic-arthritis-in-the-presta-study-analysis-in-patients-from-central-and-eastern-europe
#9
Nemanja Damjanov, Sarolta Karpati, Lajos Kemeny, Noemi Bakos, Branislav Bobic, Maria Majdan, Witold Tlustochowicz, Petr Vitek, Eva Dokoupilova, Emre Aldinc, Annette Szumski
BACKGROUND: Data are limited on the effectiveness of anti-TNF and other biologics on psoriatric arthritis (PsA) in Central and Eastern Europe (CEE). The objective of this analysis was to evaluate the efficacy of etanercept (ETN) in PsA patients from CEE. METHODS: In PRESTA, patients were randomised to receive ETN 50 mg BIW or 50 mg QW for 12 weeks (double-blind phase), and ETN 50 mg QW for 12 additional weeks (open-label). In this analysis only patients from Czech Republic, Hungary, Poland, and Serbia were included...
May 16, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28505128/a-proposal-for-a-study-on-treatment-selection-and-lifestyle-recommendations-in-chronic-inflammatory-diseases-a-danish-multidisciplinary-collaboration-on-prognostic-factors-and-personalised-medicine
#10
Vibeke Andersen, Uffe Holmskov, Signe Bek Sørensen, Mohamad Jawhara, Karina W Andersen, Anette Bygum, Lone Hvid, Jakob Grauslund, Jimmi Wied, Henning Glerup, Ulrich Fredberg, Jan Alexander Villadsen, Søren Geill Kjær, Jan Fallingborg, Seyed A G R Moghadd, Torben Knudsen, Jacob Brodersen, Jesper Frøjk, Jens F Dahlerup, Ole Haagen Nielsen, Robin Christensen, Anders Bo Bojesen, Grith Lykke Sorensen, Steffen Thiel, Nils J Færgeman, Ivan Brandslund, Allan Stensballe, Erik Berg Schmidt, Andre Franke, David Ellinghaus, Philip Rosenstiel, Jeroen Raes, Berit Heitmann, Mette Boye, Charlotte Lindgaard Nielsen, Lars Werner, Jens Kjeldsen, Torkell Ellingsen
Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome...
May 15, 2017: Nutrients
https://www.readbyqxmd.com/read/28502609/switching-from-originator-infliximab-to-biosimilar-ct-p13-compared-with-maintained-treatment-with-originator-infliximab-nor-switch-a-52-week-randomised-double-blind-non-inferiority-trial
#11
Kristin K Jørgensen, Inge C Olsen, Guro L Goll, Merete Lorentzen, Nils Bolstad, Espen A Haavardsholm, Knut E A Lundin, Cato Mørk, Jørgen Jahnsen, Tore K Kvien
BACKGROUND: TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity. METHODS: The study is a randomised, non-inferiority, double-blind, phase 4 trial with 52 weeks of follow-up...
May 11, 2017: Lancet
https://www.readbyqxmd.com/read/28502334/ap-1-expression-and-its-clinical-relevance-in-immune-disorders-and-cancer
#12
REVIEW
Shivtia Trop-Steinberg, Yehudit Azar
The inflammatory response is known to have a significant role in certain autoimmune diseases and malignancies. We review current knowledge regarding the functions of activator protein 1 (AP-1) as an important modulator in several immune disorders and carcinomas. AP-1 is overexpressed in rheumatoid arthritis and in long-term allogeneic hematopoietic stem cell transplantation survivors; however, decreased expression of AP-1 has been observed in psoriasis, systematic lupus erythematosus and in patients who do not survive after hematopoietic stem cell transplantation...
May 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28501801/a-rare-coding-allele-in-ifih1-is-protective-for-psoriatic-arthritis
#13
Ashley Budu-Aggrey, John Bowes, Philip E Stuart, Matthew Zawistowski, Lam C Tsoi, Rajan Nair, Deepak Rohit Jadon, Neil McHugh, Eleanor Korendowych, James T Elder, Anne Barton, Soumya Raychaudhuri
OBJECTIVES: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. While many common risk alleles have been reported for association with PsA as well as psoriasis, few rare coding alleles have yet been identified. METHODS: To identify rare coding variation associated with PsA risk or protection, we genotyped 41 267 variants with the exome chip and investigated association within an initial cohort of 1980 PsA cases and 5913 controls. Genotype data for an independent cohort of 2234 PsA cases and 5708 controls was also made available, allowing for a meta-analysis to be performed with the discovery dataset...
May 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28499587/the-phosphodiesterase-4-inhibitor-apremilast-inhibits-th1-but-promotes-th17-responses-induced-by-6-sulfo-lacnac-slan-dendritic-cells
#14
Stephanie Oehrl, Hridayesh Prakash, Annette Ebling, Nina Trenkler, Priscila Wölbing, Anja Kunze, Thomas Döbel, Marc Schmitz, Alexander Enk, Knut Schäkel
BACKGROUND: The phosphodiesterase 4 (PDE4) inhibitor apremilast increases cellular cAMP levels and has proven effective in the treatment of psoriasis and psoriasis arthritis. We recently described 6-sulfo LacNAc dendritic cells (slanDCs) as immature DCs in blood and as a subset of inflammatory dermal DCs in psoriasis with a pronounced capacity to produce proinflammatory cytokines and to program Th17/Th1 T cell responses. OBJECTIVE: The aim of this study was to investigate possible immune regulatory effects of the PDE4 inhibitor apremilast on slanDCs...
April 20, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28496328/association-between-use-of-disease-modifying-antirheumatic-drugs-and-diabetes-in-patients-with-ankylosing-spondylitis-rheumatoid-arthritis-or-psoriasis-psoriatic-arthritis-a-nationwide-population-based-cohort-study-of-84-989-patients
#15
Hsin-Hua Chen, Der-Yuan Chen, Chi-Chen Lin, Yi-Ming Chen, Kuo-Lung Lai, Ching-Heng Lin
PURPOSE: The aim of this study is to investigate the association between the use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PSA). PATIENTS AND METHODS: This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PS/PSA who initiated treatment with anti-tumor necrosis factor (anti-TNF) drugs or nonbiologic DMARDs...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28493493/neutrophil-lymphocyte-ratio-platelet-lymphocyte-ratio-and-mean-platelet-volume-in-japanese-patients-with-psoriasis-and-psoriatic-arthritis-response-to-therapy-with-biologics
#16
Akihiko Asahina, Naoko Kubo, Yoshinori Umezawa, Hiromi Honda, Koichi Yanaba, Hidemi Nakagawa
Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range of comorbidities. The aim of this study was to evaluate the clinical significance of novel inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) in Japanese patients with plaque-type psoriasis (PsV) and psoriatic arthritis (PsA). One hundred and eighty-six patients with PsV and 50 patients with PsA treated with biologics, including infliximab, adalimumab and ustekinumab, were retrospectively analyzed before and after treatment...
May 11, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28490011/new-interleukins-in-psoriasis-and-psoriatic-arthritis-patients-the-possible-roles-of-interleukin-33-to-interleukin-38-in-disease-activities-and-bone-erosions
#17
Jiang Li, Lei Liu, Wenlong Rui, Xiangyu Li, Dandan Xuan, Shucong Zheng, Yiyun Yu, Jiong Zhang, Ning Kong, Xiaoxia Zhu, Hejian Zou, Weiguo Wan, Yu Xue
OBJECTIVES: New interleukins (ILs), especially members of IL-1 and IL-12 families, have recently been reported to be involved in the development and regulation of autoimmune and inflammatory diseases. In this study, we aimed to explore the impact of these new ILs in psoriasis (Ps) and psoriatic arthritis (PsA). METHODS: Forty PsA patients, 20 Ps patients, and 20 healthy controls (HCs) were recruited. Blood samples were obtained for detecting the levels of ILs, IL-12/23p40, and tumor necrosis factor α (TNF-α)...
May 10, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28485176/the-role-of-il-17-in-the-treatment-of-psoriatic-arthritis
#18
Ennio Lubrano, Fabio Massimo Perrotta
Psoriatic arthritis (PsA) is a chronic inflammatory articular disease characterized by psoriasis, synovitis and enthesitis. Current treatment of PsA is mainly based on the use of classical and biological DMARDs; however, 30-40% of patients could not respond to these or have a loss of response. Areas covered: Recently, the discovery of new pathogenic mechanisms have made possible the development of new drugs that target the IL-17 with the possibility to interfere with the Th17 cells that are considered the cell type mainly involved in the development of the inflammation in PsA...
May 9, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28482887/economic-burden-of-comorbidities-in-psoriasis-patients-in-the-united-states-results-from-a-retrospective-u-s-database
#19
Steven R Feldman, Haijun Tian, Isabelle Gilloteau, Patrick Mollon, Meng Shu
BACKGROUND: Psoriasis is a multifactorial, inflammatory, skin disease associated with various comorbidities. The cost of those comorbidities is not well characterized. The present study assesses the incremental burden of comorbidities on healthcare resource utilization, direct costs and indirect costs associated with short-term disabilities among patients with psoriasis in the United States. METHODS: A retrospective, U.S. cohort analysis was conducted using a large claims database...
May 8, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28482858/tight-controlled-dose-reduction-of-biologics-in-psoriasis-patients-with-low-disease-activity-a-randomized-pragmatic-non-inferiority-trial
#20
Selma Atalay, Juul M P A van den Reek, Lieke J van Vugt, Marisol E Otero, Peter C M van de Kerkhof, Alfons A den Broeder, Wietske Kievit, Elke M G J de Jong
BACKGROUND: Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that dose tapering combined with tight control of disease activity is successful. For psoriasis patients the lowest effective dose of biologics needs to be determined. The objective was to assess whether dose tapering of biologics guided by Psoriasis Area and Severity Index (PASI) and Dermatology Quality of Life Index (DLQI) scores in psoriasis patients with controlled disease activity is non-inferior (NI) to usual care...
May 8, 2017: BMC Dermatology
keyword
keyword
56034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"